Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly paclitaxel plus AMG 386 vs paclitaxel plus placebo in recurrent partially platinum-sensitive or resistant ovarian cancer
2010-019821-32Phase 3Completed
- Sponsor
- Amgen
- Start
- Sep 2010
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Paclitaxel + AMG 386 with Paclitaxel + placebo (2 arms). Primary endpoint: Progression-free survival. Started Sep 2010; status: completed.
02
Drugs
trebananib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2010-019821-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019821-32.